Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors

Jae Hee Cho

doi:10.4166/kjg.2016.68.3.169

Journal List > Korean J Gastroenterol > v.68(3) > 1007559

Go to TopGo to Top Go to BottomGo to Bottom

TOOLS

Cho: Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors

Research Update

Korean J Gastroenterol 2016;68(3):169-171.

Published online: 4 October 2016

DOI: https://doi.org/10.4166/kjg.2016.68.3.169

Antitumor Effects of Somatostatin Analogs in Gastroenteropancreatic Neuroendocrine Tumors

Jae Hee Cho

Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, Incheon, Korea

Correspondence to: Jae Hee Cho, Division of Gastroenterology, Department of Internal Medicine, Gachon University Gil Medical Center, 21 Namdong-daero 774 beon- gil, Namdong-gu, Incheon 21565, Korea. Tel: +82-32-460-3778, Fax: +82-32-460-3408, E-mail: jhcho9328@gmail.com

This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Article

Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors

References

1. Caplin ME, Pavel M, Ćwikła JB, et al. Lanreotide in metastatic enteropancreatic neuroendocrine tumors. N Engl J Med. 2014; 371:224–233.

2. Cho JH, Song SY, Lee TH, et al. Gastroenteropancreatic neuroendocrine tumor. 1st ed.Seoul: Korean Society of Gastrointestinal Cancer;2012.

3. Sun JM, Jung HC. Gastrointestinal carcinoid tumor. Korean J Gastroenterol. 2004; 44:59–65.

4. Neuroendocrine Tumors (Version 2.2016). [Internet]. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); [updated 2016 May 25;cited 2016 Jun 1]. Available from:. http://www.nccn.org/professionals/physician_gls/pdf/neuroendocrine.pdf.

5. Yao JC, Shah MH, Ito T, et al. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364:514–523.

6. Raymond E, Dahan L, Raoul JL, et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N Engl J Med. 2011; 364:501–513.

7. Aparicio T, Ducreux M, Baudin E, et al. Antitumour activity of somatostatin analogues in progressive metastatic neuroendocrine tumours. Eur J Cancer. 2001; 37:1014–1019.

8. Saltz L, Trochanowski B, Buckley M, et al. Octreotide as an anti-neoplastic agent in the treatment of functional and nonfunctional neuroendocrine tumors. Cancer. 1993; 72:244–248.

9. Arnold R, Trautmann ME, Creutzfeldt W, et al. Somatostatin analogue octreotide and inhibition of tumour growth in metastatic endocrine gastroenteropancreatic tumours. Gut. 1996; 38:430–438.

10. Rinke A, Müller HH, Schade-Brittinger C, et al. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID Study Group. J Clin Oncol. 2009; 27:4656–4663.

TOOLS

Similar articles